5 May 2022 - NICE's expert group RAPID C-19, set up to ‘to ensure safe and timely patient access to treatments that show evidence of benefit in preventing and treating COVID-19’ have confirmed that “neither NICE nor its expert group RAPID C-19 carried out a review of any of the 18 papers” specifically on vitamin C for the treatment of COVID-19, which they had previously listed as ‘clinically relevant’.

A head to head trial of vitamin C compared with an anti-viral drug, the former being inexpensive, safe and well researched, the latter being the opposite, would be revealing.

Read BMJ article